From New Mechanisms to New Standards of Care
Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 06 Feb 2020
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
News / 23 Jan 2020
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
News / 07 Jan 2020
Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
Ridinilazole for CDI
Find out more about our precision antibiotic ridinilazole for the treatment of CDI
R&D Day
A webcast replay is available of the event held in New York on 7 October 2019
AIM Delisting FAQs
A set of frequently asked questions about the AIM delisting is available for download